BACKGROUND: Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. METHODS: Serum samples from control subjects and patients with benign or malignant prostatic disease were analyzed on antibody arrays targeting multiple candidate prostate cancer markers and detected with two-color, rolling-circle amplification (TC-RCA). The measurements of certain antibodies were validated using immunoblots, immunoprecipitation/mass spectrometry, and sandwich immunoassays. RESULTS: Several potential disease-associated protein alterations were uncovered. The most significant was thrombospondin-1, which was strongly elevated in patients with benign prostatic disease and repressed in patients with prostate cancer. Thrombospondin-1 levels did not correlate with prostate-specific antigen (PSA) levels and differentiated benign from malignant disease with 79% sensitivity and 81% specificity. CONCLUSIONS: The measurement of thrombospondin-1 could be used to assist the decision to obtain a biopsy in men with suspected prostate cancer, which could lead to a reduction in the number of unnecessary prostatic biopsies. (c) 2006 Wiley-Liss, Inc.
BACKGROUND: Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. METHODS: Serum samples from control subjects and patients with benign or malignant prostatic disease were analyzed on antibody arrays targeting multiple candidate prostate cancer markers and detected with two-color, rolling-circle amplification (TC-RCA). The measurements of certain antibodies were validated using immunoblots, immunoprecipitation/mass spectrometry, and sandwich immunoassays. RESULTS: Several potential disease-associated protein alterations were uncovered. The most significant was thrombospondin-1, which was strongly elevated in patients with benign prostatic disease and repressed in patients with prostate cancer. Thrombospondin-1 levels did not correlate with prostate-specific antigen (PSA) levels and differentiated benign from malignant disease with 79% sensitivity and 81% specificity. CONCLUSIONS: The measurement of thrombospondin-1 could be used to assist the decision to obtain a biopsy in men with suspected prostate cancer, which could lead to a reduction in the number of unnecessary prostatic biopsies. (c) 2006 Wiley-Liss, Inc.
Authors: Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll Journal: Lab Invest Date: 2010-05-10 Impact factor: 5.662
Authors: Jochen M Schwenk; Ulrika Igel; Maja Neiman; Hanno Langen; Charlotte Becker; Anders Bjartell; Fredrik Ponten; Fredrik Wiklund; Henrik Grönberg; Peter Nilsson; Mathias Uhlen Journal: Mol Cell Proteomics Date: 2010-08-03 Impact factor: 5.911
Authors: Xristo Zárate; David C Henderson; Keenan C Phillips; April D Lake; David W Galbraith Journal: Proteome Sci Date: 2010-06-15 Impact factor: 2.480
Authors: Malin Nordström; Christer Wingren; Carsten Rose; Anders Bjartell; Charlotte Becker; Hans Lilja; Carl A K Borrebaeck Journal: Proteomics Clin Appl Date: 2014-10-22 Impact factor: 3.494
Authors: Niclas Olsson; Christer Wingren; Mikael Mattsson; Peter James; David O'Connell; Fredrik Nilsson; Dolores J Cahill; Carl A K Borrebaeck Journal: Mol Cell Proteomics Date: 2011-06-14 Impact factor: 5.911